<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180659</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-814</org_study_id>
    <nct_id>NCT02180659</nct_id>
  </id_info>
  <brief_title>A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants</brief_title>
  <acronym>PRO-814</acronym>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Titan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Titan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate maintenance of treatment efficacy when
      transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg
      or less of sublingual (SL) buprenorphine (BPN), to 4 Probuphine implants compared to SL BPN.

      The secondary objective of the study is to confirm safety of 4 Probuphine implants in adult
      outpatients with opioid dependence who are clinically stabilized on 8 mg or less of SL BPN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, double-dummy, active-controlled multi-center study to
      evaluate the efficacy of transition to four 80 mg Probuphine implants in adult outpatients
      with opioid dependence, who are clinically stabilized on 8 mg or less of SL BPN. The study
      will include 3 Phases; Screening, Maintenance and Follow-up.

      Medical and eligibility screening should occur within 2 weeks of the first Maintenance Phase
      visit. The Screening Visit will include standard medical screening procedures, complete
      medical/psychosocial history, urine toxicology and detailed substance use and treatment
      history.

      All subjects who have provided written informed consent and have met the other study entry
      criteria will be eligible for randomization. Following confirmation of eligibility, subjects
      will be randomized to one of two treatment groups in a 1:1 ratio:

        -  Treatment Group A: Daily SL BPN tablets (≤8 mg/daily) + four placebo implants

        -  Treatment Group B: Four 80 mg Probuphine implants + daily SL placebo tablets

      Implants will be surgically inserted on Day 1 (Baseline and Initiation of Study Drugs Visit).
      On Post-Implant Visit, additional follow-up safety and implant assessment procedures will be
      conducted. Subjects will return for monthly study visits on Weeks 4, 8, 12, 16, 20, and 24
      (End of Treatment Visit). In addition to the monthly scheduled visits, subjects will provide
      4 random urine toxicology samples throughout the 24-week treatment period.

      A total of 10 urine toxicology samples will be collected; 6 at scheduled visits (1 per month)
      and 4 at random urine toxicology visits throughout the 24-week treatment period. At the
      scheduled visits, other assessments of efficacy and safety will be collected. Implants will
      be removed at the End of Treatment Visit on Week 24.

      Following Week 24, subjects will be re-transitioned back to usual care (pre-trial), as
      needed. During Week 25, telephone contact will be made with all subjects. and Week 26 will
      include an on-site visit to the clinic for final follow-up assessments (Follow-up Visit).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid Use.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary efficacy endpoint is a responder analysis. A subject will be designated as a responder (meaning they have maintained stability) if they have no more than 2 of 6 months with any evidence of illicit opioid use. Evidence of illicit opioid use is defined as a positive opioid urine toxicology result or self-reported illicit opioid use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With no Urine Illicit Opioid Use by Month;</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary outcome is the percent of subjects with no urine illicit opioid use by month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Evidence of Urine Illicit Opioid Use by Month</measure>
    <time_frame>24 weeks</time_frame>
    <description>Secondary efficacy endpoint measures number of participants with evidence of urine illicit opioid use by month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With no Self-reported Illicit Drug Use by Month</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjects in the ITT population with no self-reported use of any illicit drugs (opioid or non-opioid) by month of evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Craving: Desire to Use Visual Analogue Scale (VAS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary outcome of measures of craving: desire to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no desire, and 100 mm is strongest possible desire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Withdrawal: Clinical Opiate Withdrawal Scale (COWS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary outcome measures the change in baseline in the Clinical opiate withdrawal scale (COWS), which is a scale consisting of 11 common opiate withdrawal signs or symptoms, rated on a numeric scale with higher scores associated with greater withdrawal symptoms. A total score was calculated as the sum of the responses to the 11 signs/symptoms for a total range of 0-48. Withdrawal severity was classified, based on the total score, as follows: 0-4=none/normal, 5-12=mild, 13-24=moderate, 25-36=moderately severe, more than 36=severe withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Withdrawal: Subjective Opioid Withdrawal Scale (SOWS) (ITT Population)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary outcome measures the change in baseline in the subjective opioid withdrawal scale (SOWS), which is a scale which is a subject self-assessment of withdrawal symptoms. The scale consists of 16 questions that rate the intensity of withdrawal from 0 (not at all) to 4 (extremely) with a cumulative score ranging from 0-64 (0 =not at all, 64=extremely)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of Craving: Need to Use Visual Analogue Scale (VAS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary outcome of measures of craving: Need to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no need, and 100 mm is strongest possible need.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>buprenorphine implants + placebo tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four 80 mg Probuphine implants + daily SL placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine tablets + placebo implants</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual buprenorphine tablets</intervention_name>
    <arm_group_label>buprenorphine tablets + placebo implants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine implant</intervention_name>
    <arm_group_label>buprenorphine implants + placebo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo implants</intervention_name>
    <arm_group_label>buprenorphine tablets + placebo implants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sublingual placebo tablets</intervention_name>
    <arm_group_label>buprenorphine implants + placebo tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must provide written informed consent prior to the conduct of any
             study-related procedures.

          2. Male or female, 18-65 years of age, inclusive.

          3. Primary diagnosis of opioid dependence (DSM-IV-TR).

          4. Subject is considered clinically stable by their treating healthcare provider and
             confirmed by the following:

               1. Subject must be on SL BPN treatment for at least 6 months.

               2. Subject must have been on a SL BPN dose of 8 mg or less daily for at least the
                  last 90 days prior to Screening.

               3. No positive urine toxicology results for illicit opioids in the last 90 days.

          5. Free from significant withdrawal symptoms (score of ≤ 5 on the Clinical Opiate
             Withdrawal Scale [COWS]), as measured at the Screening Visit.

          6. Female subjects of childbearing potential must be willing to use a reliable method of
             contraception during the entire study (Screening Visit to Follow-Up Visit).

        Exclusion Criteria:

          1. Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS).

          2. Current diagnosis of chronic pain syndrome requiring chronic opioid treatment, or
             conditions associated with acute episodic flares that require opioid treatment.

          3. Pregnant or lactating or planning to become pregnant during the study.

          4. Hypersensitivity or allergy to ethylene vinyl acetate (EVA)-containing substances or
             naloxone.

          5. Recent scarring or tattoos on their upper arms, or a history of keloid scarring.

          6. Requires current use of agents metabolized through CYP 3A4 such as azole antifungals
             (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or protease
             inhibitors (e.g., ritonavir, indinavir, and saquinavir).

          7. History of coagulopathy within the past 90 days, and/or current anti-coagulant therapy
             such as warfarin.

          8. Current DSM-IV-TR diagnosis for substance dependence on any other psychoactive
             substances other than opioids or nicotine (e.g., alcohol, cocaine).

          9. Significant symptoms or other factors which in the opinion of the Investigator would
             preclude compliance with the protocol, subject safety, adequate cooperation in the
             study, or obtaining informed consent.

         10. Current medical conditions such as severe respiratory insufficiency that may prevent
             the subject from safely participating in study.

         11. Any pending legal action that could prohibit participation or compliance in the study.

         12. Exposure to any investigational drug within the 8 weeks prior to Screening.

         13. Aspartate aminotransferase levels ≥3 X the upper limit of normal, alanine
             aminotransferase levels ≥ 3 X the upper limit of normal, total bilirubin ≥ 1.5 X the
             upper limit of normal, or creatinine ≥ 1.5 X upper limit of normal on the Screening
             laboratory assessments.

         14. Clinically significant low platelet count on the Screening laboratory assessments,
             according to the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <results_first_submitted>June 12, 2017</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 26 June 2014. Last patient completed: 18 May 2015
A total of 21 Investigators participated in the study, across 21 sites in the United States.</recruitment_details>
      <pre_assignment_details>211 patient were screened and of those,177 subjects were enrolled and randomized into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine Implants + Placebo Tablets</title>
          <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine Tablets + Placebo Implants</title>
          <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89">N=90 randomized, however N=89 received study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject incarcerated during conduct</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AT REQUEST OF THE SPONSOR</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine Implants + Placebo Tablets</title>
          <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine Tablets + Placebo Implants</title>
          <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="21" upper_limit="63.0"/>
                    <measurement group_id="B2" value="39" lower_limit="22" upper_limit="64.0"/>
                    <measurement group_id="B3" value="39" lower_limit="21" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="14" upper_limit="46.4"/>
                    <measurement group_id="B2" value="27" lower_limit="19" upper_limit="50.6"/>
                    <measurement group_id="B3" value="28" lower_limit="14" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary opioid of abuse</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prescription opioid pain reliever</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Heroin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first opioid abuse</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" lower_limit="1.4" upper_limit="36.6"/>
                    <measurement group_id="B2" value="11.5" lower_limit="1.6" upper_limit="45.6"/>
                    <measurement group_id="B3" value="11.3" lower_limit="1.4" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from first diagnosis of opioid dependence</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" lower_limit="0.5" upper_limit="34.6"/>
                    <measurement group_id="B2" value="6.2" lower_limit="0.6" upper_limit="43.6"/>
                    <measurement group_id="B3" value="6.2" lower_limit="0.5" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Buprenorphine Treatment (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="0.5" upper_limit="10.0"/>
                    <measurement group_id="B2" value="3.4" lower_limit="0.4" upper_limit="10.0"/>
                    <measurement group_id="B3" value="3.5" lower_limit="0.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest Dose of Buprenorphine Treatment Ever Taken (mg/day)</title>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="2.0" upper_limit="32.0"/>
                    <measurement group_id="B2" value="14" lower_limit="4.0" upper_limit="36.0"/>
                    <measurement group_id="B3" value="14" lower_limit="2.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dose of BPN treatment prior to randomization.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>2 mg/d</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 mg/d</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 mg/d</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 mg/d</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid Use.</title>
        <description>The primary efficacy endpoint is a responder analysis. A subject will be designated as a responder (meaning they have maintained stability) if they have no more than 2 of 6 months with any evidence of illicit opioid use. Evidence of illicit opioid use is defined as a positive opioid urine toxicology result or self-reported illicit opioid use.</description>
        <time_frame>24 weeks</time_frame>
        <population>The analyses included 173 subjects in the ITT population who received treatment and post-baseline evaluations.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Efficacy Endpoint is a Responder Rate Analysis, Where a Responder is Defined as a Patient With no More Than 2 of 6 Months With Any Evidence of Illicit Opioid Use.</title>
          <description>The primary efficacy endpoint is a responder analysis. A subject will be designated as a responder (meaning they have maintained stability) if they have no more than 2 of 6 months with any evidence of illicit opioid use. Evidence of illicit opioid use is defined as a positive opioid urine toxicology result or self-reported illicit opioid use.</description>
          <population>The analyses included 173 subjects in the ITT population who received treatment and post-baseline evaluations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For the primary efficacy variable, a test of non-inferiority of Probuphine (active) versus SL BPN (control) responders was conducted. A non-inferiority margin of 20% was employed to define noninferiority.
A Confidence Interval (CI) for the difference in proportions was calculated, and non-inferiority was established if the lower bound of the 95% CI for the difference of proportions (Probuphine – SL BPN) was greater than –0.20.</non_inferiority_desc>
            <p_value>&lt;.001</p_value>
            <method>Chi-squared</method>
            <param_type>Difference in Response Rate</param_type>
            <param_value>0.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With no Urine Illicit Opioid Use by Month;</title>
        <description>The secondary outcome is the percent of subjects with no urine illicit opioid use by month.</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With no Urine Illicit Opioid Use by Month;</title>
          <description>The secondary outcome is the percent of subjects with no urine illicit opioid use by month.</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>At month 6 comparing those subject with no illicit drug use.</non_inferiority_desc>
            <p_value>0.306</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Evidence of Urine Illicit Opioid Use by Month</title>
        <description>Secondary efficacy endpoint measures number of participants with evidence of urine illicit opioid use by month.</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evidence of Urine Illicit Opioid Use by Month</title>
          <description>Secondary efficacy endpoint measures number of participants with evidence of urine illicit opioid use by month.</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.037</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With no Self-reported Illicit Drug Use by Month</title>
        <description>Subjects in the ITT population with no self-reported use of any illicit drugs (opioid or non-opioid) by month of evaluation</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With no Self-reported Illicit Drug Use by Month</title>
          <description>Subjects in the ITT population with no self-reported use of any illicit drugs (opioid or non-opioid) by month of evaluation</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeek 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24/EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Craving: Desire to Use Visual Analogue Scale (VAS)</title>
        <description>The secondary outcome of measures of craving: desire to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no desire, and 100 mm is strongest possible desire.</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Craving: Desire to Use Visual Analogue Scale (VAS)</title>
          <description>The secondary outcome of measures of craving: desire to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no desire, and 100 mm is strongest possible desire.</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="13.98"/>
                    <measurement group_id="O2" value="6.8" spread="16.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="17.69"/>
                    <measurement group_id="O2" value="-1.5" spread="13.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="10.63"/>
                    <measurement group_id="O2" value="-2.2" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="9.37"/>
                    <measurement group_id="O2" value="-2.2" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="11.88"/>
                    <measurement group_id="O2" value="-2.3" spread="17.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="10.94"/>
                    <measurement group_id="O2" value="-3.8" spread="16.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="11.15"/>
                    <measurement group_id="O2" value="-2.8" spread="19.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparing change in baseline to week 24 between the two groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Withdrawal: Clinical Opiate Withdrawal Scale (COWS)</title>
        <description>The secondary outcome measures the change in baseline in the Clinical opiate withdrawal scale (COWS), which is a scale consisting of 11 common opiate withdrawal signs or symptoms, rated on a numeric scale with higher scores associated with greater withdrawal symptoms. A total score was calculated as the sum of the responses to the 11 signs/symptoms for a total range of 0-48. Withdrawal severity was classified, based on the total score, as follows: 0-4=none/normal, 5-12=mild, 13-24=moderate, 25-36=moderately severe, more than 36=severe withdrawal.</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Withdrawal: Clinical Opiate Withdrawal Scale (COWS)</title>
          <description>The secondary outcome measures the change in baseline in the Clinical opiate withdrawal scale (COWS), which is a scale consisting of 11 common opiate withdrawal signs or symptoms, rated on a numeric scale with higher scores associated with greater withdrawal symptoms. A total score was calculated as the sum of the responses to the 11 signs/symptoms for a total range of 0-48. Withdrawal severity was classified, based on the total score, as follows: 0-4=none/normal, 5-12=mild, 13-24=moderate, 25-36=moderately severe, more than 36=severe withdrawal.</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="15.18"/>
                    <measurement group_id="O2" value="6.0" spread="13.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="12.70"/>
                    <measurement group_id="O2" value="-1.2" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="11.45"/>
                    <measurement group_id="O2" value="-1.9" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="11.12"/>
                    <measurement group_id="O2" value="-2.4" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="15.36"/>
                    <measurement group_id="O2" value="-2.3" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="12.03"/>
                    <measurement group_id="O2" value="-3.4" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="12.58"/>
                    <measurement group_id="O2" value="-1.9" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.922</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Withdrawal: Subjective Opioid Withdrawal Scale (SOWS) (ITT Population)</title>
        <description>The secondary outcome measures the change in baseline in the subjective opioid withdrawal scale (SOWS), which is a scale which is a subject self-assessment of withdrawal symptoms. The scale consists of 16 questions that rate the intensity of withdrawal from 0 (not at all) to 4 (extremely) with a cumulative score ranging from 0-64 (0 =not at all, 64=extremely)</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Withdrawal: Subjective Opioid Withdrawal Scale (SOWS) (ITT Population)</title>
          <description>The secondary outcome measures the change in baseline in the subjective opioid withdrawal scale (SOWS), which is a scale which is a subject self-assessment of withdrawal symptoms. The scale consists of 16 questions that rate the intensity of withdrawal from 0 (not at all) to 4 (extremely) with a cumulative score ranging from 0-64 (0 =not at all, 64=extremely)</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.85"/>
                    <measurement group_id="O2" value="2.2" spread="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="55.56"/>
                    <measurement group_id="O2" value="0.3" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.39"/>
                    <measurement group_id="O2" value="0.4" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.53"/>
                    <measurement group_id="O2" value="-0.1" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.23"/>
                    <measurement group_id="O2" value="-0.4" spread="4.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.47"/>
                    <measurement group_id="O2" value="-0.1" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24(Change from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.26"/>
                    <measurement group_id="O2" value="0.1" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.425</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Craving: Need to Use Visual Analogue Scale (VAS)</title>
        <description>The secondary outcome of measures of craving: Need to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no need, and 100 mm is strongest possible need.</description>
        <time_frame>24 weeks</time_frame>
        <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Implants + Placebo Tablets</title>
            <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine Tablets + Placebo Implants</title>
            <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Craving: Need to Use Visual Analogue Scale (VAS)</title>
          <description>The secondary outcome of measures of craving: Need to use is a change from Day 1 (baseline) in the unipolar visual analogue scale (VAS), which is a 0-100 mm scale, where 0 mm is no need, and 100 mm is strongest possible need.</description>
          <population>Outcome measures were obtained for all subjects as described in the Analysis Population Description of the primary outcome above.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="15.18"/>
                    <measurement group_id="O2" value="6.0" spread="13.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="12.70"/>
                    <measurement group_id="O2" value="-1.2" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="11.45"/>
                    <measurement group_id="O2" value="-1.9" spread="16.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="11.12"/>
                    <measurement group_id="O2" value="-2.4" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="15.36"/>
                    <measurement group_id="O2" value="-2.3" spread="15.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="12.03"/>
                    <measurement group_id="O2" value="-3.4" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24(Change from BL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="12.58"/>
                    <measurement group_id="O2" value="-1.9" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparing change in baseline to week 24 between the two groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>ANOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were documented and followed from the time the subject signed the ICF until 14 days after the EOT Visit (i.e., implant removal and discontinuation of SL BPN/placebo treatment) which was approximately 28 weeks. Serious adverse events and AEs designated as possibly related to study drug were followed until resolution or stabilization.</time_frame>
      <desc>For the purpose of this report, AEs considered by the investigator to be possibly, probably, or definitely related to study drug are classified as study drug-related events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine Implants + Placebo Tablets</title>
          <description>Four 80 mg Probuphine implants + daily SL placebo tablets
Buprenorphine implant
sublingual placebo tablets</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine Tablets + Placebo Implants</title>
          <description>Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
sublingual buprenorphine tablets
placebo implants</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.15</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion - Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Pediatric exposure to treatment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Beebe DeVarney</name_or_title>
      <organization>Titan Pharmaceuticals</organization>
      <phone>650-244-4990</phone>
      <email>kdevarney@titanpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

